Ocular Therapeutix Inc (OCUL)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $1.37B
Last updated: Nov 17, 2026 at 4:15 PM ET
Ocular Therapeutix Inc (OCUL) Stock Chart
Ocular Therapeutix (OCUL) has a latest price of $6.02 on Nov 17, 2026, 63.4% below its 52-week high of $16.44. Its price fell 46.7% over the past 12 months. The month-end price rose 23.1% over the 10 years through Oct 2026, a compound annual rate of 2.1%.
Price Chart
From Oct 2016 to Oct 2026, its highest month-end close was $20.70 in Dec 2020 and its lowest $2.48 in Nov 2023, adjusted for splits.
Month-end closes, adjusted for splits. Dividends are not included.
Chart OCUL with Advanced Charting
Daily candlesticks, valuation multiples, side-by-side comparisons and drawings for OCUL.
Free with a GNG account. No credit card.
Price Performance
Over the past 3 months the price fell 48.7%, and over 6 months it fell 24.7%. The month-end price rose 144.6% over the 3 years through Oct 2026, a compound annual rate of 34.7%.
| Period | Change |
|---|---|
| 1 month | -4.3% |
| 3 months | -48.7% |
| 6 months | -24.7% |
| 12 months | -46.7% |
| 12 months, with dividends | -46.7% |
| Period | Change | Per year |
|---|---|---|
| 3 years | +144.6% | +34.7% |
| 5 years | +5.0% | +1.0% |
| 10 years | +23.1% | +2.1% |
Price by Year
Its best calendar year was 2020, when the price rose 424.1%, and its weakest was 2021, when it fell 66.3%.
| Year | Close | Change |
|---|---|---|
| 2026 through Oct 2026 | $6.97 | -42.6% |
| 2025 | $12.14 | +42.2% |
| 2024 | $8.54 | +91.5% |
| 2023 | $4.46 | +58.7% |
| 2022 | $2.81 | -59.7% |
| 2021 | $6.97 | -66.3% |
| 2020 | $20.70 | +424.1% |
| 2019 | $3.95 | -0.8% |
| 2018 | $3.98 | -10.6% |
| 2017 | $4.45 | -46.8% |
Trading Range
The price is 22.8% below its 50-day average of $7.79 and 32.2% below its 200-day average of $8.87.
| Measure | Value | Price vs |
|---|---|---|
| Latest price (Nov 17, 2026) | $6.02 | |
| 52-week high | $16.44 | -63.4% |
| 52-week low | $5.94 | +1.3% |
| 50-day average | $7.79 | -22.8% |
| 200-day average | $8.87 | -32.2% |
Price Risk
Over 3 years, its largest fall from a peak was 62.7%.
| Measure | Value |
|---|---|
| 1-year beta | 1.43 |
| Largest fall, 1 year | -62.7% |
| Largest fall, 3 years | -62.7% |
Advanced Charting Features
Advanced Charting is free with a GNG account, and signed-in members get it in place of the price chart above.
- Valuation multiples. Daily P/E, price to sales, cash flow and book value, PEG and PEGY, drawn behind the price wherever the company's data supports them.
- Price charts and drawings. Candlestick, OHLC, line and area charts with volume and earnings, dividend and split markers, plus trend lines, levels and notes kept in your account.
- Side-by-side compare. Two stocks next to each other on one metric and time span, each chart with its own price scale.
- Projections and saved views. Pick a start and an end point to see the price return, dividends and total return between them, and save views to open later.
Frequently Asked Questions About OCUL
What is OCUL's 1-year price change?
Ocular Therapeutix's price fell 46.7% over the past 12 months. With dividends included, the 12-month total return was -46.7%.
What is OCUL's 5-year price change?
Ocular Therapeutix's month-end price rose 5.0% over the 5 years through Oct 2026, a compound annual rate of 1.0%. These figures leave out dividends.
What is OCUL's 52-week high and low?
Ocular Therapeutix's 52-week high is $16.44 and its 52-week low is $5.94. Its latest price of $6.02 on Nov 17, 2026 is 63.4% below the high.
What is OCUL's beta?
Ocular Therapeutix's 1-year beta against the S&P 500 is 1.43, so its price has moved more than the market over the past year. Its largest fall from a peak over the past year was 62.7%.
Is the OCUL chart free?
Yes. Advanced Charting for OCUL is free with a GNG account, and no credit card is needed. It adds daily candlestick and line charts with volume, valuation multiples, side-by-side comparisons, drawings and saved views.
OCUL pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors